Human Genome Epidemiology Literature Finder
Records 1 - 3 (of 3 Records) |
Query Trace: Disease Progression and CFI[original query] |
---|
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. The Lancet. Oncology 2020 5 21 (5): 710-722. Ledermann Jonathan A, Oza Amit M, Lorusso Domenica, Aghajanian Carol, Oaknin Ana, Dean Andrew, Colombo Nicoletta, Weberpals Johanne I, Clamp Andrew R, Scambia Giovanni, Leary Alexandra, Holloway Robert W, Gancedo Margarita Amenedo, Fong Peter C, Goh Jeffrey C, O'Malley David M, Armstrong Deborah K, Banerjee Susana, García-Donas Jesus, Swisher Elizabeth M, Cameron Terri, Maloney Lara, Goble Sandra, Coleman Robert |
Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial. British journal of cancer 2020 Feb . Aparicio Thomas, Bennouna Jaafar, Le Malicot Karine, Boige Valérie, Taieb Julien, Bouché Olivier, Phelip Jean-Marc, François Eric, Borel Christian, Faroux Roger, Dahan Laetitia, Bachet Jean-Baptiste, Egreteau Joelle, Kaminsky Marie-Christine, Gornet Jean-Marc, Cojocarasu Oana, Gasmi Mohamed, Guerin-Meyer Véronique, Lepage Côme, Ghiringhelli François, |
Disease progression and costs at the 3-year follow-up of the GERAS-US study. Alzheimer's & dementia (Amsterdam, Netherlands) 2023 4 15 (2): e12430. Julie M Chandler, Dorene M Rentz, Anthony Zagar, Yongin Kim, Ronald L Schwartz, Howard Fill |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 29, 2024
- Content source: